Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Coronavirus vaccine - Sanofi pasteur

Drug Profile

Coronavirus vaccine - Sanofi pasteur

Alternative Names: COVID-19

Latest Information Update: 02 Mar 2020

At a glance

  • Originator National Institute of Allergy and Infectious Diseases; sanofi pasteur
  • Developer Biomedical Advanced Research and Development Authority; Sanofi Pasteur
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical COVID 2019 infections
  • Discontinued Severe acute respiratory syndrome

Most Recent Events

  • 24 Feb 2020 Sanofi Pasteur reinitiates the development of coronavirus vaccine in collaboration with Biomedical Advanced Research and Development Authority
  • 24 Feb 2020 Preclinical development for COVID-2019-infections in USA (Parenteral)
  • 18 Feb 2020 Sanofi Pasteur collaborates with Biomedical Advance Research and Development Authority (BARDA) from US Department of Health and Human Services for development of coronavirus vaccine

Development Overview

Introduction

Coronavirus vaccine is an inactivated virus vaccine and is being developed by Sanofi pasteur (formerly Aventis Pasteur) for the preventive treatment of COVID-2019 infections. The development of the vaccine will be based on the prior preclinical studies done on a Severe Acute Respiratory Syndrome (SARS) vaccine candidate and will be done in collaboration with Biomedical Advanced Research And Development Authority (BARDA). Sanofi Pasteur will utlilise its recombinant DNA platform, that produces an exact genetic match to proteins that are found on the surface of the coronavirus. The DNA of baculovirus expression platform will be combined with the DNA sequence encoding the coronavirus antigen. The large quantities of coronavirus antigen generated will in turn be formulated to stimulate the immune system and protect against the virus. Preclinical development is underway in the US.

Earlier Sanofi Pasteur was collaborating with the US National Institute of Allergy and Infectious Diseases (NIAID) to research and develop a SARS vaccine. However, NIAID is no more involved in the development of the vaccine and the development in SARS indication is discontinued.

In January 2005, Aventis Pasteur changed its name to sanofi pasteur.

Company Agreements

In February 2020, Sanofi and US Department of Health and Human Services entered into an agreement to advance the development of a coronavirus vaccine based on Sanofi's previous development work for serious acute respiratory syndrome (SARS) vaccine. Sanofi will work in collaboration with Biomedical Advanced Research And Development Authority (BARDA) and utlilise its recombinant DNA platform, which produces an exact genetic match to proteins that are found on the surface of the coronavirus. [1]

Aventis Pasteur (later sanofi pasteur) had entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID) to research and develop an inactivated coronavirus vaccine against Severe Acute Respiratory Syndrome (SARS). Under the agreement, which was signed on 26 September 2003, sanofi pasteur would develop the vaccine candidate using a similar approach to that of the licensed inactivated polio vaccine.

Key Development Milestones

In February 2020, Sanofi announced that the preclinical studies done by Protein Sciences (acquired by Sanofi), prior to 2017, on the SARS vaccine candidate was immunogenic and afforded partial protection in animal challenge models. These results will form a basis for further development of Coronavirus vaccine [1] .

Sanofi pasteur is also participating in the Canadian SARS Research Consortium, a public-private effort to coordinate, promote and support research on SARS, including vaccine development [2] .

Drug Properties & Chemical Synopsis

  • Route of administration Parenteral
  • Formulation unspecified
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • WHO ATC code

    J07B-X (Other viral vaccines)

  • EPhMRA code

    J7 (Vaccines)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - Prevention Preclinical USA Parenteral / unspecified Biomedical Advanced Research and Development Authority, Sanofi Pasteur 18 Feb 2020
Severe acute respiratory syndrome - - Discontinued (Preclinical) France unspecified / unspecified Sanofi Pasteur 30 Dec 2005

Commercial Information

Involved Organisations

Organisation Involvement Countries
sanofi pasteur Originator France
National Institute of Allergy and Infectious Diseases Originator USA
National Institute of Allergy and Infectious Diseases Owner USA
sanofi pasteur Owner France
Biomedical Advanced Research and Development Authority Collaborator USA

Development History

Event Date Update Type Comment
24 Feb 2020 Active Status Review Sanofi Pasteur reinitiates the development of coronavirus vaccine in collaboration with Biomedical Advanced Research and Development Authority [1] Updated 02 Mar 2020
24 Feb 2020 Phase Change - Preclinical Preclinical development for COVID-2019-infections in USA (Parenteral) [1] Updated 02 Mar 2020
18 Feb 2020 Company Involvement Sanofi Pasteur collaborates with Biomedical Advance Research and Development Authority (BARDA) from US Department of Health and Human Services for development of coronavirus vaccine [1] Updated 02 Mar 2020
18 Feb 2020 Phase Change - Preclinical Preclinical trials in COVID-2019-infections (Prevention) in USA (Parenteral) [1] Updated 02 Mar 2020
30 Dec 2005 Phase Change - Discontinued(Preclinical) Discontinued - Preclinical for Severe acute respiratory syndrome in France (unspecified route) Updated 17 Mar 2009
19 Jan 2005 Company Involvement Aventis Pasteur is now called sanofi pasteur Updated 19 Jan 2005
27 Aug 2004 Company Involvement Aventis has merged with Sanofi-Synthelabo to form sanofi-aventis Updated 27 Aug 2004
20 Oct 2003 Phase Change - Preclinical Preclinical trials in Severe acute respiratory syndrome in France (unspecified route) Updated 20 Oct 2003

References

  1. Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine.

    Media Release
  2. Aventis and NIH Enter Into SARS Vaccine R&D Pact.

    Media Release
Back to top